908 Shares in CME Group Inc. (NASDAQ:CME) Acquired by Nixon Peabody Trust Co.

Nixon Peabody Trust Co. acquired a new stake in CME Group Inc. (NASDAQ:CME - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 908 shares of the financial services provider's stock, valued at approximately $241,000.

A number of other hedge funds have also modified their holdings of the company. Spire Wealth Management grew its holdings in CME Group by 37.4% during the fourth quarter. Spire Wealth Management now owns 1,320 shares of the financial services provider's stock worth $307,000 after acquiring an additional 359 shares during the period. Boston Trust Walden Corp boosted its position in CME Group by 6.0% in the 4th quarter. Boston Trust Walden Corp now owns 16,569 shares of the financial services provider's stock worth $3,848,000 after purchasing an additional 935 shares in the last quarter. Trust Point Inc. boosted its position in CME Group by 7.6% in the 4th quarter. Trust Point Inc. now owns 1,021 shares of the financial services provider's stock worth $237,000 after purchasing an additional 72 shares in the last quarter. Calamos Wealth Management LLC acquired a new position in shares of CME Group in the 4th quarter valued at $207,000. Finally, Brown Lisle Cummings Inc. boosted its holdings in CME Group by 252.0% during the fourth quarter. Brown Lisle Cummings Inc. now owns 352 shares of the financial services provider's stock worth $82,000 after buying an additional 252 shares in the last quarter. 87.75% of the stock is owned by institutional investors and hedge funds.

CME Group Price Performance

CME stock traded down $0.66 during midday trading on Friday, reaching $274.24. The stock had a trading volume of 1,635,928 shares, compared to its average volume of 2,184,401. CME Group Inc. has a 52-week low of $190.70 and a 52-week high of $290.79. The company has a current ratio of 1.01, a quick ratio of 1.02 and a debt-to-equity ratio of 0.10. The company's fifty day simple moving average is $271.45 and its 200 day simple moving average is $252.61. The company has a market cap of $98.82 billion, a price-to-earnings ratio of 28.36, a price-to-earnings-growth ratio of 6.76 and a beta of 0.45.

CME Group (NASDAQ:CME - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The financial services provider reported $2.80 earnings per share for the quarter, topping analysts' consensus estimates of $2.61 by $0.19. CME Group had a net margin of 57.52% and a return on equity of 13.62%. The firm had revenue of $1.64 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same period in the previous year, the business posted $2.50 earnings per share. CME Group's quarterly revenue was up 10.4% on a year-over-year basis. As a group, sell-side analysts predict that CME Group Inc. will post 10.49 earnings per share for the current fiscal year.

CME Group Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 25th. Stockholders of record on Monday, June 9th will be issued a dividend of $1.25 per share. This represents a $5.00 annualized dividend and a dividend yield of 1.82%. The ex-dividend date of this dividend is Monday, June 9th. CME Group's dividend payout ratio is currently 50.30%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on CME. Morgan Stanley upped their price objective on shares of CME Group from $301.00 to $304.00 and gave the stock an "overweight" rating in a research report on Thursday, April 24th. Raymond James raised CME Group from a "market perform" rating to an "outperform" rating and set a $287.00 price target for the company in a report on Monday, March 10th. Erste Group Bank lowered CME Group from a "strong-buy" rating to a "hold" rating in a report on Saturday, May 24th. Barclays boosted their price objective on CME Group from $279.00 to $283.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 23rd. Finally, Keefe, Bruyette & Woods increased their target price on CME Group from $265.00 to $273.00 and gave the company a "market perform" rating in a research report on Thursday, April 24th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $258.20.

Insider Activity

In other CME Group news, Director Phyllis M. Lockett sold 1,060 shares of the business's stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $277.88, for a total value of $294,552.80. Following the transaction, the director now directly owns 3,108 shares in the company, valued at $863,651.04. The trade was a 25.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Martin J. Gepsman sold 300 shares of the firm's stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $273.17, for a total transaction of $81,951.00. Following the sale, the director now owns 24,767 shares of the company's stock, valued at $6,765,601.39. This represents a 1.20% decrease in their position. The disclosure for this sale can be found here. Insiders sold 22,900 shares of company stock worth $6,147,935 over the last ninety days. Corporate insiders own 0.30% of the company's stock.

CME Group Company Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.